Hedge Funds Anticipate Another IPO

Biopharma companies are confident there is appetite for their shares.

(Paul Yeung/Bloomberg)

(Paul Yeung/Bloomberg)

Another hedge-fund-sponsored biopharmaceutical company has set its terms for going public.

Oric Pharmaceuticals said it plans to offer 6.3 million shares at between $14 and $16 per share. Earlier in the week it had filed plans to offer 5 million shares in the same price range.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.